BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Moderna COVID Vaccine Stimulates Twice the Antibody Response as Pfizer-BioNTech

  Belgium researchers compared the Moderna and Pfizer-BioNTech COVID-19 vaccines and found that the Moderna jabs generated twice the antibodies than the Pfizer-BioNTech vaccine.

  September 1, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Astellas Pauses Dosing of Gene Therapy After Liver-Linked Concerns

  The company announced it paused the screening and dosing of an investigational gene therapy for patients with XLMTM following a serious adverse event report in a trial participant.

  September 1, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  VectivBio Expands Rare Disease Pipeline with Comet Therapeutics Acquisition

  Adding to its list of achievements, on Tuesday the Swiss biotech announced it is acquiring Comet Therapeutics.

  September 1, 2021

   · 

  2 min read

   · 

  Ellen Bombela
• 

  FDA

  Mesoblast’s COVID-19 Respiratory Therapy Hits Another Snag on Route to Potential EUA

  Mesoblast shares dropped on the last day of August 2021 after it was told that its candidate COVID-19 treatment needs to undergo another trial to be green-lit for emergency approval by the FDA.

  September 1, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Deals

  Global Roundup: VectivBio Acquires Comet Therapeutics to Expand Rare Disease Pipeline

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  September 1, 2021

   · 

  5 min read

   · 

  Alex Keown
• 

  Business

  Many Cytokine Space Parallels Drawn by Asher Bio’s Series B

  Asher Bio began two years ago and raised $55 million in a Series A financing round this March to take forward a series of engineered cytokines that aim to eliminate both the toxicities and the loss of efficacy in immunotherapy.

  September 1, 2021

   · 

  4 min read

   · 

  BioSpace Editorial Staff
• 

  Business

  Growing Pains at BIO as Price Control Debate Heats Up in Washington and Within the Industry

  Multiple reports suggest an exodus of BIO team members over price control issues. BIO reorganized its leadership structure to provide what was expected to be “long-term stability for the organization.”

  September 1, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Janssen Wins FDA Approval for Long-Acting Schizophrenia Drug Invega Hafyera

  FDA greenlit Janssen’s Invega Hafyera, the first long-acting antipsychotic drug of its kind that provides six months’ control of symptoms with a single dose.

  September 1, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Merck, Ridgeback Embark on Phase III with COVID-19 Therapeutic

  The study of Molnupiravir will assess 1,300 adult participants 18 and over who cohabitate with someone who has tested positive for the coronavirus and is symptomatic.

  September 1, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Pharm Country

  Leading Medical Journal Validates Potential of Zentalis-discovered Cancer Therapy

  ZN-c3 is a WEE1 inhibitor that could be used as monotherapy for uterine serous carcinoma and solid tumors, as well as combination therapy for ovarian cancer, alongside chemotherapy.

  September 1, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN